Short answer
Protalix BioTherapeutics, Inc. (PLX) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $18M (down 0.6% year over year) with net income of $2M.
Q3 2025 key financials · XBRL
- Revenue
- $18M
- −0.6% YoY · +14.0% QoQ
- Net income
- $2M
- −27.2% YoY · +1336.0% QoQ
- Operating margin
- 11.9%
- EPS (diluted)
- $0.03
- −25.0% YoY · +200.0% QoQ
Source: XBRL data from the Protalix BioTherapeutics, Inc. (PLX) Q3 2025 10-Q on SEC EDGAR. USD.
Protalix BioTherapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Elfabrio: CHMP negative opinion on proposed 2 mg/kg E4W regimen
- PRX-115: FDA IND effective, phase 2 trial expected to initiate in fourth quarter 2025
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2024 Form 10-K
- Carried-forward regulatory and compliance risks unchanged from the prior annual filing
- Carried-forward operational and competitive risks unchanged from the prior annual filing
- Carried-forward liquidity, debt, currency, and concentration risks unchanged from the prior annual filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protalix BioTherapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.